A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 — Stella

Recruiting

Back to Schizophrenia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Beijing AnDing Hospital Capital Medical University, Beijing

Key details

Phase

Early testing

Sponsor

Luye Pharma Group Ltd.

Enrollment target

~40 participants

Started

August 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 60 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov